New Malaria Drug Launched in Latin America, Southeast Asia　(1/2)


A Brazilian drug company and a nonprofit group have developed a new, simplified malaria treatment.  Patients have to take only one tablet a day for three days for some ages, or two tablets a day for three days for other ages.

The medicine combines two existing malaria drugs, artesunate and mefloquine. This combination has been widely used in recent years in Latin America and Southeast Asia.

The Brazilian government will make the new treatment available throughout Latin America and Southeast Asia over this year and next. The fixed-dose drug will be offered to public agencies at a target price of two and a half dollars for the full adult treatment.

Bernard Pecoul is head of the nonprofit group, called the Drugs for Neglected Diseases Initiative. He says the new formulation is safe and fast-acting, and effective for children and adults.

The World Health Organization says artemisinin-based combination treatments are the best way to treat common malaria. Research shows that the simpler the treatment, the more likely people are to complete it. People increase the risk of drug resistance when they do not complete a full treatment.

参考译文：
一家巴西药厂和一个非盈利性组织共同研发了一种疟疾治疗的简化新疗法。根据不同的年龄,病人只需每天服用一片药片,连服三天.或每天服用两片药片,连服三天.

此种药片由两种现已用于治疗疟疾的药物青蒿琥酯和甲氟喹合成,近年来广泛使用于拉丁美洲和东南亚地区.
巴西政府将在今年和明年在整个拉丁美洲和东南亚推广该疗法. 这种固定剂量的药物将以2.5美元的标价提供给政府用于成人治疗。

Bernard Pecoul是这家非盈利组织“被忽略疾病药物研发组织(DNDi)”的领导者。他说，新配方是一种对儿童和成人都安全且迅速有效的治疗方法。

世界卫生组织称,以青蒿素为基础的合成治疗法是治疗疟疾的最好方法.研究表明，治疗越简单，人们越容易完成。如果人们无法完成完整的治疗，他们对药物的耐药性风险就会增加。





TAG: voa,voa下载,voa慢速英语,voa英语,voa news,voa english,voa special,voa听力,美国之音